Moore, Erica http://orcid.org/0000-0002-5789-1727
Reynolds, Joshua A. http://orcid.org/0000-0002-8797-7003
Davidson, Anne
Gallucci, Stefania
Morel, Laurence http://orcid.org/0000-0002-6622-1290
Rao, Deepak A. http://orcid.org/0000-0001-9672-7746
Young, Howard A. http://orcid.org/0000-0002-3118-5111
Putterman, Chaim
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32-GM007288, T32-GM007288)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR076557)
U.S. Department of Defense (W81XWH-17-1-0657)
Lupus Research Alliance
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI128901)
Article History
First Online: 10 May 2021
Competing interests
: C.P. is a consultant to Equillium and is one of the investigators on the current anti-CD6 antibody treatment trial for lupus. The other authors declare no competing interests.